Company news

Cognition Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

February 27, 2025

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

February 26, 2025

Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

February 25, 2025

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

February 20, 2025

Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference

February 5, 2025

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

January 29, 2025

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

January 7, 2025

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

December 17, 2024

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

November 25, 2024

Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

November 24, 2024

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

November 12, 2024

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

November 11, 2024

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

October 30, 2024

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

October 28, 2024

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

October 22, 2024

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

October 21, 2024

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

October 1, 2024

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

September 30, 2024

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

September 2, 2024

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

August 21, 2024

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

August 7, 2024

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

August 4, 2024

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

July 28, 2024

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8: 30am ET on Monday July 29, 2024

July 25, 2024

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

July 1, 2024

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease

May 20, 2024

Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update

May 6, 2024

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

April 28, 2024

Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease

April 21, 2024

Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference

April 1, 2024

Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024

March 31, 2024

Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update

March 25, 2024

Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results

March 14, 2024

Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock

March 13, 2024

Cognition Therapeutics Announces Proposed Public Offering of Common Stock

March 10, 2024

Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock

March 10, 2024

Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies

March 5, 2024

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

February 25, 2024

New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812

February 5, 2024

Cognition Therapeutics CEO Issues Letter to Shareholders

January 3, 2024

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

November 15, 2023

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

November 14, 2023

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

November 6, 2023

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

October 26, 2023

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

October 23, 2023

Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications

October 15, 2023

Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD

September 6, 2023

Cognition Therapeutics Announces Participation in Upcoming September Conferences

August 29, 2023

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 7, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 31 decks. Every deck is listed under its year.